Topics

Macro/Op-Ed Practice Science & Tech Money

Resources

Earn CE Editorial Advisory Board Free Samples HR Hub Magazine Submission Guidelines Videos Webcasts White Papers

User Tools

About Us Advertise Contact Us Press Releases Privacy Policy Subscribe Terms & Conditions

https://www.facebook.com/DentalEconomics

https://www.instagram.com/dentaleconomicsofficial/

https://www.linkedin.com/company/dental-economics?trk=biz-brand-tree-co-name

https://twitter.com/DentistryIQ

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.0549 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Adaptimmune Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022 ↗

November 09, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 08, 2022

Gainers

Via Benzinga

Adaptimmune Reports Third-Quarter Financial Results and Business Update

November 08, 2022

Adaptimmune will focus on programs in MAGE-A4 and PRAME, two of the most validated T-Cell targets in solid tumors Adaptimmune will...

Via Newsfile

Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday ↗

November 09, 2022

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.

Via Benzinga

Why Adaptimmune Therapeutics Stock Is Glowing Green Today ↗

November 08, 2022

Positive trial data is powering the biotech's stock higher today.

Via The Motley Fool

Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers

November 08, 2022

New responses in ovarian and urothelial cancers increase ORR to 52% from 44% in heavily pre-treated patients with late-stage ovarian,...

Via Newsfile

Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022

October 27, 2022

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 27, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...

Via Newsfile

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 25, 2022

Gainers DBV Technologies (NASDAQ:DBVT) stock increased by 18.7% to $1.9 during Tuesday's after-market session. The company's market cap stands at $356.7 million.

Via Benzinga

GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day ↗

October 25, 2022

Via Benzinga

Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK

October 25, 2022

Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 –GSK to deliver data from the ongoing...

Via Newsfile

Domino's Pizza To $385? Plus This Analyst Cuts Price Target On Adaptimmune Therapeutics By Around 79% ↗

October 04, 2022

UBS cut the price target on Domino's Pizza, Inc. (NYSE: DPZ) from $430 to $385. Domino's shares rose 4% to $329.11 on Tuesday.

Via Benzinga

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary ↗

September 09, 2022

Via Benzinga

Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers ↗

September 09, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 09, 2022

Via Benzinga

Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors

September 09, 2022

- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian,...

Via Newsfile

Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials

August 25, 2022

- Event to be held on Friday, September 9th, at 8 a.m. EDT -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp....

Via Newsfile

Adaptimmune Therapeutics: Q2 Earnings Insights ↗

August 04, 2022

Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Adaptimmune Reports Second-Quarter Financial Results and Business Update

August 04, 2022

- Reaffirming financial guidance; Company funded into early 2024 -- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission...

Via Newsfile

Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022

July 21, 2022

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...

Via Newsfile

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 03, 2022

Via Benzinga

Adaptimmune Therapeutics's Return On Capital Employed Insights ↗

June 03, 2022

Benzinga Pro data, Adaptimmune Therapeutics (NASDAQ:ADAP) reported Q1 sales of $3.58 million. Earnings fell to a loss of $50.27 million, resulting in a 29.36% decrease from last quarter.

Via Benzinga

Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track

May 26, 2022

- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) --...

Via Newsfile

69 Biggest Movers From Friday ↗

June 06, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 16, 2022

Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 12.7% to $1.6 during Monday's after-market session. The market value of their outstanding shares is at $258.9 million.

Via Benzinga

Adaptimmune Therapeutics: Q1 Earnings Insights ↗

May 09, 2022

Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q1 earnings results on Monday, May 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

A Preview Of Adaptimmune Therapeutics's Earnings ↗

May 06, 2022

Adaptimmune Therapeutics (NASDAQ:ADAP) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Adaptimmune Therapeutics Q1 2022 Earnings Conference Call On May 9, 2022 At 08:00 AM ET ↗

May 04, 2022

Adaptimmune Therapeutics (NASDAQ:ADAP) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Looking Into Adaptimmune Therapeutics's Return On Capital Employed ↗

March 16, 2022

According to Benzinga Pro data, during Q4, Adaptimmune Therapeutics (NASDAQ:ADAP) posted sales of $1.42 million. Earnings were up 8.36%, but Adaptimmune Therapeutics still...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 15, 2022

Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

https://www.facebook.com/DentalEconomics

https://www.instagram.com/dentaleconomicsofficial/

https://www.linkedin.com/company/dental-economics?trk=biz-brand-tree-co-name

https://twitter.com/DentistryIQ

About Us
Contact Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions